Latest Hedgehog signaling pathway Stories
CAMBRIDGE, Mass., Oct. 16, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc.
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech, Inc.
Curis, Inc. (NASDAQ:CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that the Company will release its second quarter financial results on Wednesday, July 30, 2008 before the market opens.
U.S. medical scientists say a set of promising new anti-cancer agents called hedgehog antagonists might present a risk for people with heart disease. Researchers at the Washington University School of Medicine in St.
Researchers at the University of Wisconsin School of Medicine and Public Health (SMPH) are wagging a finger at currently held notions about the way digits are formed.
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced that it has entered into an agreement to sell and assign its remaining BMP-7 technologies to Stryker Corporation.
The Quaking gene, first described as a mutation in mice that causes rapid tremor, is thought to suppress tumor formation and protect humans from cancer.
New studies in mice have shown that immature stem cells that proliferate to form brain tissues can function for at least a year â€” most of the life span of a mouse â€” and give rise to multiple types of neural cells, not just neurons. The discovery may bode well for the use of these neural stem cells to regenerate brain tissue lost to injury or disease.
- The parings of haberdine; also, any kind of fragments.